Cytoreductive nephrectomy may improve survival in papillary kidney cancer

A recent study presented at the 2018 Genitourinary Cancer Symposium in San Francisco in February reports that surgery to remove the affected kidney (cytoreductive nephrectomy) from patients with metastatic papillary renal cell carcinoma (pRCC) may improve overall survival. Of 353 patients with metastatic pRCC, 244 patients underwent cytoreductive nephrectomy and had significantly longer median overall […]

read more

Axitinib plus pembrolizumab combination shows promise for advanced kidney cancer

Data from a recent phase 1b study has shown that a combination of axitinib and pembrolizumab treatment for advanced renal cell carcinoma (RCC) is safe and tolerable, and exhibits promising anti-tumour activity in previously untreated patients. The study data were presented at the 2018 Genitourinary Cancers Symposium held in San Francisco last week. The researchers […]

read more

Quality of life outcomes similar for cabozantinib and everolimus

Data from the phase 3 METEOR trial published in the Journal of Clinical Oncology recently show that treatment of advanced kidney cancer patients with cabozantinib resulted in similar quality of life (QoL) outcomes as for patients treated with everolimus. Cabozantinib also improved progression-free survival (PFS), overall survival (OS), and overall response rate (ORR) compared with everolimus. The […]

read more

Crizotinib shows promise in type 1 papillary kidney cancer

Papillary kidney cancer is a rare subtype of renal cell carcinoma (RCC), and is characterised by changes in a gene called MET. The CREATE study from the European Organisation for the Research and Treatment of Cancer (EORTC) investigated crizotinib in patients with type 1 papillary RCC. Twenty-three (23) patients were treated, only 4 of which […]

read more

Non-steroidal anti-inflammatory drugs may improve survival in kidney cancer

A new study published in the International Journal of Cancer suggests that non-steroidal anti-inflammatory drugs (NSAIDs), angiotensin converting enzyme inhibitors (ACEis), and selective serotonin reuptake inhibitors (SSRIs) may improve survival rates in patients with kidney cancer. The aim of the study was to evaluate the association between use of commonly-prescribed medications with potential anti-cancer effects and survival […]

read more

Smoking after diagnosis with renal cell carcinoma may lead to worse cancer-specific survival

Smoking is a known risk factor for the development of renal cell carcinoma (RCC), and has been proven in a number of studies, such as the Nurses’ Health Study and the Health Professionals Follow-Up Study, a prospective study including almost 1,500 people published in 2005, and data from the Surveillance, Epidemiology, and End Results (SEER) Program database […]

read more

Sunitinib approved by the FDA for adjuvant treatment of advanced kidney cancer

The US Food and Drug Administration (FDA) has approved sunitinib (Sutent) for adjuvant treatment of adults who have had their kidney cancer removed, but who are at high risk of the cancer returning. Sunitinib is a tyrosine kinase inhibitor (TKI) that works by blocking several enzymes that promote cell growth and the formation of new […]

read more

Nivolumab improves survival of kidney cancer patients at three years

Updated results from the phase 3 CheckMate-025 study, presented at the 16th International Kidney Cancer Symposium in Miami, USA last week, show a three-year survival benefit of nivolumab (Opdivo) over everolimus (Afinitor) in advanced renal cell carcinoma (RCC). The risk of death was also reduced by 26% for the people taking nivolumab. CheckMate-025 evaluated previously […]

read more

Predictors of outcome of nivolumab therapy for metastatic kidney cancer discovered in blood samples

The measurement of immune-inflammation index, neutrophil-lymphocyte ratio, and platelet-lymphocyte ratio in the blood have been found to be robust predictors of outcome of nivolumab therapy for metastatic renal cell carcinoma (RCC). Immune-inflammation index was found to be a more powerful predictor than the other inflammatory indexes, and a low immune-inflammation index was found to be […]

read more

Overweight people fare better with kidney cancer

It is well known that obesity is a risk factor for kidney cancer. However, a recent study finds that people with kidney cancer who are overweight or obese tend to live longer than those who are normal weight or under-weight. The researchers investigated 4 databases of over 9,000 people with advanced kidney cancer. In one […]

read more
Showing 141 to 150 of 150 results
  TOP